S197: NAVITOCLAX PLUS RUXOLITINIB IN JAK INHIBITOR-NAÏVE PATIENTS WITH MYELOFIBROSIS: PRELIMINARY SAFETY AND EFFICACY IN A MULTICENTER, OPEN-LABEL PHASE 2 STUDY - F. Passamonti; J. Foran; A. Tandra; V. De Stefano; M. Laura Fox; A. Mattour; M. F. McMullin; A. C. Perkins; G. Rodriguez-Macías; H. Sibai; Q. Qin; J. Potluri; et al. (HemaSphere, 2022)